Clinical trial

Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

NCT07172126

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-09-01

PhasePHASE1 / PHASE2

Study timeline

Study start (estimated)2025-09-01Date precision: month

Registry last updated2025-09-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Castration-resistant Prostate Cancerunresolved

Interventions

TQB3201 tabletsDRUG

Sponsors & collaborators

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.lead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1 ChongqingChongqing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07172126 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.